ClinicalTrials.gg
RecruitingNCT05410925OPTIMA-6Updated Oct 30, 2026

Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction

A Phase 4 interventional study of Recombinant staphylokinase and Placebo in ST Elevation Myocardial Infarction, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 61 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.
Updated Oct 30, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,260
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies in ST Elevation Myocardial Infarction with a site in China — 40 open to participants now, 43 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · China.

Planned enrollment
17th of 97
2,260 · median 320
Started
2023
with 7 others
Phase 4
25 of 146
4 open now
Primary completion
2026-12
later than 13 of 42 live
Registered
97th of 146
by date

Among the 146 studies in ST Elevation Myocardial Infarction with a site in China, this one is the 17th largest by planned enrollment of the 97 interventional ones that give a count, is one of 8 that started in 2023, is one of 25 in phase 4, reaches primary completion later than 13 of the 42 other live ones, and was the 97th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

40 of the 146 studies in ST Elevation Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in ST Elevation Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

As an effective treatment for acute ST-segment elevation myocardial infarction (STEMI), early reperfusion may reduce the infarct size and improve the prognosis of patients. However, it remains uncertain whether adjunctive thrombolytic therapy administered immediately prior to primary percutaneous coronary intervention (PCI) improves outcomes in patients undergoing the procedure within 120 minutes.

In this investigator-initiated, prospective, multi-center, randomized, double-blind, placebo-controlled trial, subjects meeting the inclusion/exclusion criteria should be randomly assigned 1:1 to the trial group (r-SAK) or the control group (placebo). The risk of major adverse cardiovascular events within 90 days will be observed.

Read the detailed description

Acute myocardial infarction (AMI) is a serious and critical disease that causes acute coronary artery stenosis, spasm or occlusion due to the rupture or erosion of coronary artery plaque, resulting in myocardial ischemia and necrosis. Myocardial ischemia and necrosis can cause myocardial cell loss, ventricular remodeling and local inflammatory reaction, leading to decreased cardiac output or increased intracardiac pressure, and eventually progress to heart failure (HF), which seriously affects the prognosis of patients. The FAST-MI study found that 37.5% of AMI patients were complicated with HF, and the 1-year mortality of these patients was significantly increased. Early reperfusion treatment as an effective means of AMI treatment can promote myocardial reperfusion, save dying myocardium and reduce infarct area, which is of great significance to improve the clinical prognosis of patients.

At this stage, many primary hospitals do not have the conditions for emergency percutaneous coronary intervention (PCI). Transferring patients to PCI hospitals takes a lot of time, delaying the best time for early reperfusion treatment. In addition, the thrombus burden in the coronary artery increases with the prolongation of ischemia time. Stent implantation in the coronary artery with excessive thrombus burden is prone to slow blood flow or no reflow, resulting in the occurrence of major adverse cardiovascular events (MACE). In view of the above problems, guidelines suggest that if the estimated transit time is more than 120 minutes, thrombolytic therapy should be performed before transport; If the estimated transfer time is less than 120 minutes, it can be directly transferred to the PCI hospital.

However, it remains uncertain whether adjunctive thrombolytic therapy administered immediately prior to primary PCI improves outcomes in patients undergoing the procedure within 120 minutes ("facilitated PCI"). Multiple previous studies comparing facilitated PCI with primary PCI found facilitated PCI to be inferior in terms of clinical outcomes, while other studies based on reduced-dose thrombolysis confirmed the superiority of facilitated PCI in better patency of infarct-related artery (IRA). Recombinant staphylokinase (r-SAK), as the third-generation thrombolytic agent, may serve as the potential thrombolytic drug to contemporary facilitated PCI by virtue of its high fibrinolytic activity and fibrin selectivity.

Staphylokinase (SAK) is produced by Staphylococcus aureus and it is a protein containing 136 amino acid residues. Its ability for dissolving blood clots was first discovered in 1948. Studies have shown that SAK is not directly convert plasminogen (PLG) into plasminogen (PLi), but first combines with PLG in a 1:1 ratio to form a complex. The complex can lead to the exposure of PLG active site, from single chain to double chain PLi, resulting to form an active SAK-PLI complex, which subsequently activates PLG molecules. Then PLG transforms into PLi and further dissolve the thrombus.

R-SAK was developed in 1990 by Shanghai Institute of Plant and Biological Physiology. It is a gene recombinant drug prepared by molecular cloning of SAK gene in Escherichia coli. Its biological characteristics are very similar to natural SAK, and r-SAK is a highly fibrin-specific fibrinolysis agent. R-SAK is considered to be one of the most promising thrombolytic drugs due to its high thrombolysis activity (especially in platelet-rich arterial thrombosis), inactivation of system fibrinolysis, and few side effects. Clinical studies have shown that the efficacy of r-SAK in the treatment of AMI is better than urokinase, comparable to RT-PA, and it does not increase serious bleeding complications such as intracranial hemorrhage.

In terms of pharmacokinetics, r-SAK has a fast distribution and a long action time in human body. Half-lives of distribution term is 13.30±2.06min and elimination term is 67.94±21.39min when intravenous injection 10 mg r-SAK in 30min. A single bolus of r-SAK as early as possible during the first medical contact (such as prehospital care or primary hospitals or medical centers with conditional PCI) can maximize the time window for reperfusion therapy.

Achieving early reperfusion by means of facilitated PCI is consistent with the core of STEMI treatment, but the efficacy and safety of facilitated PCI are still controversial. OPTIMA-6, designed as shorter symptom onset to treatment time, a half-dose thrombolytic agent, and upstream use of the potent antiplatelet agent, will therefore evaluate the efficacy and safety of a half-dose bolus of r-SAK vs. placebo prior to primary PCI to inform clinical practice of contemporary facilitated PCI in patients with STEMI.

03

Conditions studied

  • ST Elevation Myocardial Infarction

Keywords

  • ST Elevation Myocardial Infarction
  • Recombinant Staphylokinase
  • Thrombolysis
04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years, weight ≥45 kg
  2. Diagnosed as STEMI (meeting the following two conditions simultaneously)

    1. Ischemic chest pain lasts ≥ 30 minutes
    2. indicates that ST-segment elevation of two or more contiguous precordial leads ≥ 0.1 mV, or ST-segment elevation of two or more contiguous precordial leads ≥ 0.2 mV
  3. Time from onset of persistent chest pain to randomization ≤12 hours
  4. Primary PCI expected to be performed ≥30 minutes, and ≤120 minutes

Exclusion criteria

Exclusion Criteria:

  1. Cardiogenic shock
  2. Active bleeding or known at high risk of bleeding (including grade Ⅲ or Ⅳ retinopathy or retinal gastrointestinal or urinary tract hemorrhage within the past 6 month)
  3. Ischemic stroke or in the past 6 months
  4. History of hemorrhagic stroke
  5. Known intracranial aneurysm
  6. Severe trauma, surgery or head injury within 1 month
  7. Suspected aortic dissection or infective endocarditis
  8. Puncture with difficult hemostasis by compression within 1 month (e.g., visceral , compartment puncture)
  9. Currently taking anticoagulants
  10. Known history of anemia with level \<10 g/dL
  11. Known history of thrombocytopenia with count \<100×10⁹/L
  12. Poorly controlled hypertension ( ≥180/110 mmHg)
  13. Severe hepatic or renal impairment indicated by the consultation or previous history (glutamic-pyruvic transaminase or glutamic oxalacetic transaminase >3 times value; \<15 ml/min/1.73m\^2, calculated based on CKD-EPI)
  14. Known allergy to r-SAK
  15. Pregnancy, lactation, or planning for pregnancy
  16. History of chronic total occlusion, myocardial infarction or CABG
  17. Having taken antiplatelet drugs other than aspirin and ticagrelor, such as clopidogrel, prasugrel or cilostazol after the symptom onset
  18. Patients with other conditions that made them unsuitable to be recruited at the discretion of the investigators
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,260 participants (estimated)

Study arms

  • Experimental
    r-SAK group

    intravenous injection of single-bolus 5 mg r-SAK in 3 min

    Drug: Recombinant staphylokinase

  • Placebo comparator
    placebo group

    intravenous injection of placebo in 3 min

    Drug: Placebo

Interventions

  • DrugauR protein, Staphylococcus aureusStudies of auR protein, Staphylococcus aureusauR protein, Staphylococcus aureus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction

  • DrugPlacebo

    Intravenous injection of placebo is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction

06

What researchers measure

Primary outcomes

  1. MACE

    Defined as a composite of all-cause death, reinfarction, unplanned target vessel revascularization, heart failure or cardiogenic shock, major ventricular arrhythmia

    Time frame: Within 90 days

Secondary outcomes

  1. Each of the following cardiac and cerebrovascular events

    Including all-cause death, cardiovascular death, reinfarction, stroke, unplanned target vessel revascularization, heart failure or cardiogenic shock, major ventricular arrhythmia, cardiogenic rehospitalization, ventricular septal rupture, papillary muscle rupture, cardiac rupture, ventricular aneurysm

    Time frame: Within 90 days

  2. NT-proBNP

    The level of NT-proBNP

    Time frame: 1 day before discharge or day 7, day 90±3

  3. CMR indexes

    Including infarct size, left ventricular ejection fraction (LVEF), microvascular obstruction (MVO) and intramuscular hemorrhage (IMH), assessed by cardiac magnetic resonance (CMR)

    Time frame: Day 5

  4. LVEF assessed by echocardiogram

    LVEF assessed by echocardiogram

    Time frame: Day 90±3

  5. The percentage of TIMI flow grade 2 and 3 prior to PCI

    The percentage of thrombolysis in myocardial infarction (TIMI) flow grade 2 and 3 prior to PCI

    Time frame: Immediately prior to PCI

  6. The percentage of TIMI flow grade 3 prior to PCI

    The percentage of TIMI flow grade 3 prior to PCI

    Time frame: Immediately prior to PCI

  7. The percentage of TIMI flow grade 2 and 3 after PCI

    The percentage of TIMI flow grade 2 and 3 after PCI

    Time frame: Immediately after PCI

  8. The percentage of TIMI flow grade 3 after PCI

    The percentage of TIMI flow grade 3 after PCI

    Time frame: Immediately after PCI

  9. MACE

    Defined as a composite of all-cause death, reinfarction, unplanned target vessel revascularization, heart failure or cardiogenic shock, major ventricular arrhythmia

    Time frame: Within 360 days

  10. Each of the following cardiac and cerebrovascular events

    Including all-cause death, cardiovascular death, reinfarction, ischemic stroke, unplanned target vessel revascularization, heart failure or cardiogenic shock, major ventricular arrhythmia, cardiogenic rehospitalization, ventricular septal rupture, papillary muscle rupture, cardiac rupture, ventricular aneurysm

    Time frame: Within 360 days

  11. NT-proBNP

    The level of NT-proBNP

    Time frame: Day 360±7

  12. LVEF assessed by echocardiogram

    LVEF assessed by echocardiogram

    Time frame: Day 360±7

Other outcomes

  1. Major bleeding events during hospitalization or within 7 days (BARC 3, 5)

    Major bleeding events during hospitalization or within 7 days (BARC 3, 5)

    Time frame: During hospitalization or within 7 days

  2. Minor bleeding events during hospitalization or within 7 days (BARC 2)

    Minor bleeding events during hospitalization or within 7 days (BARC 2)

    Time frame: During hospitalization or within 7 days

  3. Major bleeding events within 90 days (BARC 3, 5)

    Major bleeding events within 90 days (BARC 3, 5)

    Time frame: Within 90 days

  4. Minor bleeding events within 90 days (BARC 2)

    Minor bleeding events within 90 days (BARC 2)

    Time frame: Within 90 days

07

Study locations

61 of 61 sites recruiting
  • The First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210029, China
    Recruiting
    • Chunjian Li, PHD · Contactlijay@njmu.edu.cn · +86 13701465229
    • Chen Li, MD · Contactlcicewind@outlook.com · +86 13913886986
    • Chunjian Li, PHD · Principal investigator
    • Chen Li, MD · Sub investigator
    • Tian Wu, MD · Sub investigator
  • Changzhou Second People's Hospital
    Changzhou, China
    Recruiting
    • Xin Chen, MD · Contact
  • Changzhou Wujin People's Hospital
    Changzhou, China
    Recruiting
    • Jianqiang Xiao, MD · Contact
  • The First People's Hospital of Changzhou
    Changzhou, China
    Recruiting
    • Ling Yang, MD · Contact
  • Chongqing Hospital of Jiangsu Province Hospital
    Chongqing, China
    Recruiting
    • Junhong Wang, MD · Contact
    • Hongyan Xing · Contact
  • The second Affiliated Hospital of Dalian Medical University
    Dalian, China
    Recruiting
    • Xin Zhao, MD · Contact
  • Daqing Oilfield General Hospital
    Daqing, China
    Recruiting
    • Zhiqi Sun, MD · Contact
  • Dongguan People's Hospital
    Dongguan, China
    Recruiting
    • Suxia Guo, MD · Contact
  • Fengcheng People's Hospital
    Fengcheng, China
    Recruiting
    • Wenbo Li, MD · Contact
  • General Hospital of Southern Theatre Command
    Guangzhou, China
    Recruiting
    • Jinxia Zhang, MD · Contact
  • The Second Affiliated Hospital of Hainan Medical University
    Hainan, China
    Recruiting
    • Yuewu Chen, MD · Contact
  • The Affiliated Hospital of Hangzhou Normal University
    Hangzhou, China
    Recruiting
    • Peng Dong, MD · Contact+86 13501352371
  • The Second Affiliated Hospital of Zhejiang University Medical College
    Hangzhou, China
    Recruiting
    • Jun Jiang, MD · Contact
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, China
    Recruiting
    • Xianhe Lin, MD · Contact
  • Huai'an First People's Hospital
    Huai'an, China
    Recruiting
    • Xiwen Zhang, MD · Contact
  • Huai'an Second People's Hospital
    Huai'an, China
    Recruiting
    • Naiquan Yang, MD · Contact
  • Donghai Country People's Hospital
    Lianyungang, China
    Recruiting
    • Jianling Zhou, MD · Contact
  • The First People's Hospital of Lianyungang
    Lianyungang, China
    Recruiting
    • Bo Zhao, MD · Contact
  • The Second People's Hospital of Lianyungang
    Lianyungang, China
    Recruiting
    • Yilian Wang, MD · Contact
  • Liyang Hospital of Jiangsu Province Hospital
    Liyang, China
    Recruiting
    • Junhong Wang, MD · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, China
    Recruiting
    • Xiaoping Peng, MD · Contact
  • Nanjing Tongren Hospital
    Nanjing, China
    Recruiting
    • Jiakuan Wu, MD · Contact
  • Sir Run Run Hospital Nanjing Medical University
    Nanjing, China
    Recruiting
    • Chunjian Li, MD · Contact
  • The Fourth Affiliated Hospital of Nanjing Medical University
    Nanjing, China
    Recruiting
    • Pingxi Xiao, MD · Contact
  • Nanjing Qixia District Hospital
    Nanning, China
    Recruiting
    • Daxing Yang, MD · Contact
  • Affiliated Hospital of Nantong University
    Nantong, China
    Recruiting
    • Hongzhuan Sheng, MD · Contact
  • Nantong First People's Hospital
    Nantong, China
    Recruiting
    • Koulong Zheng, MD · Contact
  • The People's Hospital of Zhalaite
    Neimeng, China
    Recruiting
    • Guofeng Chang, MD · Contact
  • Qingdao Municipal Hospital
    Qingdao, China
    Recruiting
    • Yibing Shao, MD · Contact
  • Qilu Hospital of Shandong University
    Shandong, China
    Recruiting
    • Yuguo Chen, MD · Contact
  • Renji Hospital affiliated to Shanghai Jiaotong University
    Shanghai, China
    Recruiting
    • Jun Bu, MD · Contact
  • Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, China
    Recruiting
    • Lei Hou, MD · Contact+86 13564868096
  • The People's Hospital of Liaoning Province
    Shenyang, China
    Recruiting
    • Bo Luan, MD · Contact
  • Shenzhen People's Hospital
    Shenzhen, China
    Recruiting
    • Da Yin, MD · Contact
  • Suining County People's Hospital
    Suining, China
    Recruiting
    • Ruili Wang, MD · Contact
  • Nanjing Drum Tower Hospital Group Suqian Hospital
    Suqian, China
    Recruiting
    • Hao Ding, MD · Contact
  • Suqian First Hospital
    Suqian, China
    Recruiting
    • Zhiyong Zhang, MD · Contact
  • Suzhou Dushu Lake Hospital
    Suzhou, China
    Recruiting
    • Yafeng Zhou, MD · Contact
  • Suzhou Municipal Hospital of Anhui Province
    Suzhou, China
    Recruiting
    • Hailong Qiu, MD · Contact
  • Suzhou Municipal Hospital
    Suzhou, China
    Recruiting
    • Jun Zhang, MD · Contact+86 18994427321
  • The First Affiliated Hospital of Soochow University
    Suzhou, China
    Recruiting
    • Tingbo Jiang, MD · Contact
  • Wanbei Coal-Electricity Group General Hospital
    Suzhou, China
    Recruiting
    • Kun Zhu, MD · Contact
  • Taihe County Traditional Chinese Medicine Hospital
    Taihe, China
    Recruiting
    • Daimei Ni, MD · Contact
  • Taishan People&#39;s Hospital
    Taishan, China
    Recruiting
    • Yan Chen, MD · Contact+86 13580014030
  • Taizhou People's Hospital
    Taizhou, China
    Recruiting
    • Li Zhu, MD · Contact
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, China
    Recruiting
    • Hao Zhou, MD · Contact
  • The Second Affiliated Hospital of Wenzhou Medical University
    Wenzhou, China
    Recruiting
    • Xueqiang Guan, MD · Contact
  • Affiliated Hospital of Jiangnan University
    Wuxi, China
    Recruiting
    • Xiaoyan Wang, MD · Contact
  • Wuxi People's Hospital
    Wuxi, China
    Recruiting
    • Ruxing Wang, MD · Contact
  • Wuxi Second People's Hospital
    Wuxi, China
    Recruiting
    • Yan Jin, MD · Contact
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, China
    Recruiting
    • Tongda Xu, MD · Contact
  • The People's Hospital of Jiawang District of Xuzhou City
    Xuzhou, China
    Recruiting
    • Yunjun Li, MD · Contact
  • Xuzhou Central Hospital
    Xuzhou, China
    Recruiting
    • Bing Han, MD · Contact
  • Yancheng No.1 People's Hospital
    Yancheng, China
    Recruiting
    • Yunfeng Ju, MD · Contact
  • Affiliated Hospital of Yangzhou University
    Yangzhou, China
    Recruiting
    • Kaizheng Gong, MD · Contact
  • Subei People's Hospital of Jiangsu province
    Yangzhou, China
    Recruiting
    • Yong Xie, MD · Contact
  • Fuwai Central China Cardiovascular Hospital
    Zhengzhou, China
    Recruiting
    • Xiaohui Zheng, MD · Contact
  • The 7th People's Hospital of Zhengzhou
    Zhengzhou, China
    Recruiting
    • Yong Dong, MD · Contact
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
    Recruiting
    • Zhanying Han, MD · Contact
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, China
    Recruiting
    • Wei Yuan, MD · Contact
  • Zhenjiang First People's Hospital
    Zhenjiang, China
    Recruiting
    • Tao Rui, MD · Contact
08

References and documents

Publications

  • Gulati R, Behfar A, Narula J, Kanwar A, Lerman A, Cooper L, Singh M. Acute Myocardial Infarction in Young Individuals. Mayo Clin Proc. 2020 Jan;95(1):136-156. doi: 10.1016/j.mayocp.2019.05.001. PubMed 31902409 ↗
  • Bahit MC, Kochar A, Granger CB. Post-Myocardial Infarction Heart Failure. JACC Heart Fail. 2018 Mar;6(3):179-186. doi: 10.1016/j.jchf.2017.09.015. PubMed 29496021 ↗
  • Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G, Opie L. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014 May 31;383(9932):1933-43. doi: 10.1016/S0140-6736(14)60107-0. Epub 2014 May 13. PubMed 24831770 ↗
  • Juilliere Y, Cambou JP, Bataille V, Mulak G, Galinier M, Gibelin P, Benamer H, Bouvaist H, Meneveau N, Tabone X, Simon T, Danchin N; FAST-MI Investigators. Heart failure in acute myocardial infarction: a comparison between patients with or without heart failure criteria from the FAST-MI registry. Rev Esp Cardiol (Engl Ed). 2012 Apr;65(4):326-33. doi: 10.1016/j.recesp.2011.10.027. Epub 2012 Feb 20. PubMed 22357361 ↗
  • Bradley EH, Nallamothu BK, Herrin J, Ting HH, Stern AF, Nembhard IM, Yuan CT, Green JC, Kline-Rogers E, Wang Y, Curtis JP, Webster TR, Masoudi FA, Fonarow GC, Brush JE Jr, Krumholz HM. National efforts to improve door-to-balloon time results from the Door-to-Balloon Alliance. J Am Coll Cardiol. 2009 Dec 15;54(25):2423-9. doi: 10.1016/j.jacc.2009.11.003. PubMed 20082933 ↗
  • Mangin L, Lotfi M, Puie P, Yayehd K, Ispas A, Belle L. [Management of high thrombus burden in primary PCI]. Ann Cardiol Angeiol (Paris). 2017 Dec;66(6):380-384. doi: 10.1016/j.ancard.2017.10.016. Epub 2017 Oct 31. French. PubMed 29096903 ↗
  • Bai M, Pan CL, Zhao J, Zhao CR, Zhang B, Mu ZY, Meng XX, Zhou XH, Zhu YQ, Zhang Z. [Safety and efficacy of regional transport combined with PCI model in patients with STEMI after thrombolysis in northwest China]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Aug 24;48(8):641-647. doi: 10.3760/cma.j.cn112148-20200228-00138. Chinese. PubMed 32847319 ↗
  • Schwartz R, Weiss AT, Leibowitz D, Rot D, Pollak A, Lotan C, Alcalai R. Thrombolysis followed by coronary angiography versus primary percutaneous coronary intervention in non-anterior ST-elevation myocardial infarction. J Invasive Cardiol. 2013 Dec;25(12):632-6. PubMed 24296382 ↗
  • Ren K, Gong H, Huang J, Liu Y, Dong Q, He K, Tian L, Zhang F, Yu A, Wu C. Thrombolytic and anticoagulant effects of a recombinant staphylokinase-hirudin fusion protein. Thromb Res. 2021 Dec;208:26-34. doi: 10.1016/j.thromres.2021.10.005. Epub 2021 Oct 14. PubMed 34688099 ↗
  • Vanderschueren S. [Staphylokinase for a better thrombolytic treatment of heart and platelet diseases]. Verh K Acad Geneeskd Belg. 2000;62(1):69-75. Dutch. PubMed 10769618 ↗
  • Ueshima S, Matsuo O. Development of new fibrinolytic agents. Curr Pharm Des. 2006;12(7):849-57. doi: 10.2174/138161206776056065. PubMed 16515501 ↗
  • Yamamoto J, Kawano M, Hashimoto M, Sasaki Y, Yamashita T, Taka T, Watanabe S, Giddings JC. Adjuvant effect of antibodies against von Willebrand Factor, fibrinogen, and fibronectin on staphylokinase-induced thrombolysis as measured using mural thrombi formed in rat mesenteric venules. Thromb Res. 2000 Mar 1;97(5):327-33. doi: 10.1016/s0049-3848(99)00184-x. PubMed 10709908 ↗
  • Szemraj J, Stankiewicz A, Rozmyslowicz-Szerminska W, Mogielnicki A, Gromotowicz A, Buczko W, Oszajca K, Bartkowiak J, Chabielska E. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study. Thromb Haemost. 2007 Jun;97(6):1037-45. doi: 10.1160/th06-10-0562. PubMed 17549308 ↗
  • Vakili B, Nezafat N, Negahdaripour M, Yari M, Zare B, Ghasemi Y. Staphylokinase Enzyme: An Overview of Structure, Function and Engineered Forms. Curr Pharm Biotechnol. 2017;18(13):1026-1037. doi: 10.2174/1389201019666180209121323. PubMed 29424308 ↗
  • Li CJ, Huang J, Yang ZJ, Cao KJ. Thrombolytic efficacy of native recombinant staphylokinase on femoral artery thrombus of rabbits. Acta Pharmacol Sin. 2007 Jan;28(1):58-65. doi: 10.1111/j.1745-7254.2007.00455.x. PubMed 17184583 ↗
  • Nedaeinia R, Faraji H, Javanmard SH, Ferns GA, Ghayour-Mobarhan M, Goli M, Mashkani B, Nedaeinia M, Haghighi MHH, Ranjbar M. Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion. Mol Biol Rep. 2020 Jan;47(1):819-841. doi: 10.1007/s11033-019-05167-x. Epub 2019 Nov 1. PubMed 31677034 ↗
  • Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolix M, De Man F, Benit E, Muyldermans L, Collen D, et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. Circulation. 1995 Oct 15;92(8):2044-9. doi: 10.1161/01.cir.92.8.2044. PubMed 7554180 ↗
  • Armstrong PW, Burton J, Pakola S, Molhoek PG, Betriu A, Tendera M, Bode C, Adgey AA, Bar F, Vahanian A, Van de Werf F; CAPTORS II Investigators. Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). Am Heart J. 2003 Sep;146(3):484-8. doi: 10.1016/S0002-8703(03)00312-0. PubMed 12947367 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

Of 44 non-industry phase 4 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 74. This study's planned 44 months is above that.

Counting every sponsor, half of 49 studies reached it within 34 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2022
First posted
Jun 8, 2022
StartActual
Apr 8, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 exclusion criterion edited, 2 added
What changed in the criteria
Exclusion criteria
  • EditedActive bleeding or known at high risk of bleeding (including grade Ⅲ or Ⅳ retinopathy or retinal gastrointestinal or urinary tract hemorrhage within the past 16 month)
  • AddedKnown history of anemia with hemoglobin level <10 g/dL
  • AddedKnown history of thrombocytopenia with platelet count <100×10⁹/L
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Eligibility 1 exclusion criterion edited, 2 added
    What changed in the criteria
    Exclusion criteria
    • EditedActive bleeding or known at high risk of bleeding (including grade Ⅲ or Ⅳ retinopathy or retinal gastrointestinal or urinary tract hemorrhage within the past 16 month)
    • AddedKnown history of anemia with hemoglobin level <10 g/dL
    • AddedKnown history of thrombocytopenia with platelet count <100×10⁹/L
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05410925
Responsible party
Chunjian Li (Director of Cardiology, The First Affiliated Hospital with Nanjing Medical University) — Principal investigator
First posted
Jun 8, 2022
Start date
Apr 8, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Chunjian Li, PHD
Contact
lijay@njmu.edu.cn
+86 13701465229
Chen Li, MD
Contact
lcicewind@outlook.com
+86 13913886986
Chunjian Li, PHD
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: auR protein, Staphylococcus aureus

Start the discussion